The combination of tumour necrosis factor-α -308A and interleukin-10 -1082G gene polymorphisms and increased serum levels of related cytokines: Susceptibility to vitiligo

Clinical and Experimental Dermatology

Volumn 40, Issue 1, 2015, Pages 71-77

  Aydingoz I E ^a   Kanmaz Ozer M ^b   Gedikbasi A ^c   Vural, P ^b   Dotru Abbasotlu S ^b   Uysal, M ^b  

^a ACIBADEM UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; VITILIGO; ADOLESCENT; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO; YOUNG ADULT;

EID: 84916898418     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12446     Document Type: Article

References (26)

1. Le Poole IC, Wankowics-Kalinska A, van den Wijngaard RM, et al,. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004; 9: 68-72.
2. Ongenae K, Van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
3. Maresca V, Roccella M, Roccella F, et al,. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997; 109: 310-13.
4. Birol A, Kisa U, Kurtipek GS, et al,. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 2006; 45: 992-3.
5. Moretti S, Fabbri P, Baroni G, et al,. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol 2009; 24: 849-57.
6. Grimes PE, Morris R, Avaniss-Aghajani E, et al,. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
7. Pichler R, Sfetsos K, Badics B, et al,. Lymphocyte inbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio. Wien Med Wochenschr 2009; 159: 337-41.
8. Tu CX, Gu JS, Lin XR,. Increased IL-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 2003; 31: 73-8.
9. Singh S, Singh U, Pandey SS,. Serum concentration of IL-6: IL-2: TNF-α and IFN-γ in vitiligo patients. Indian J Dermatol 2012; 57: 12-14.
10. Yu HS, Chang KL, Yu CL, et al,. Alterations in IL-6: IL-8: GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997; 108: 527-9.
11. Basak PY, Adiloglu AK, Ceyhan AM, et al,. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009; 60: 256-60.
12. Zhang XJ, Chen JJ, Liu JB,. The genetic concept of vitiligo. J Dermatol Sci 2005; 39: 137-46.
13. Mirowska-Guzel D, Gromadska G, Mach A, et al,. Association of IL1A, IL1B, ILRN, IL6: IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polich population. J Neuroimmunol 2011; 236: 87-92.
14. Baki M, Akman FE, Vural P, et al,. The combination of interleukin-10 -1082 and tumor necrosis factor-α -308 or interleukin-6 -174 genes polymorphisms suggests an association with susceptibility to Hashimoto's thyroiditis. Int Immunopharmacol 2012; 12: 543-6.
15. Settin AS, Ismail A, El-Magd MA, et al,. Genetic polymorphisms of TNF-alpha-308 (G/A), IL-10 (-1082)(G/A), IL-6 (-174)(G/C) and IL-1Ra(VNTR) in Egyptian cases with type 1 diabetes mellitus. Autoimmunity 2009; 42: 50-5.
16. Namian AM, Shahbaz S, Salmanpoor R, et al,. Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients. Arch Dermatol Res 2009; 301: 21-5.
17. Salinas-Santander M, Diaz-Garcia D, Rojas-Martinez A, et al,. Tumor necrosis factor-α -308 G/A polymorphism is associated with active vitiligo vulgaris in a northeastern Mexican population. Exp Ther Med 2012; 3: 893-7.
18. Yazici AC, Erdal ME, Kaya TI, et al,. Lack of association with TNF-alpha-308 promoter polymorphism in patients with vitiligo. Arch Dermatol Res 2006; 298: 46-9.
19. Abanmi A, Al Harthi F, Zouman A, et al,. Association of interleukin-10 gene promoter polymorphisms in Saudi patients with vitiligo. Dis Markers 2008; 24: 51-7.
20. Al-Badri AM,. Abnormal expression of MHC class II and ICAM-I by melanocytes in vitiligo. J Pathol 1993; 169: 203-6.
21. Huang CL, Nordlund JJ, Boissy R,. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002; 3: 301-8.
22. Lee AY,. Role of keratinocytes in the development of vitiligo. Ann Dermatol 2012; 24: 115-25.
23. de Waal Malefyt R, Abrams J, Bennett B, et al,. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-20.
24. Taher ZA, Lauzon G, Maguiness S, et al,. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol 2009; 161: 654-9.
25. Rousset F, Garcia E, Defrance T, et al,. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890-3.
26. Ishihara K, Hirano T,. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-68.